Literature DB >> 14755006

Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands.

Jonathan L Katz1, Theresa A Kopajtic, Gregory E Agoston, Amy Hauck Newman.   

Abstract

Previous studies demonstrated that analogs of benztropine (BZT) possess high affinity for the dopamine transporter, inhibit dopamine uptake, but generally have behavioral effects different from those of cocaine. One hypothesis is that muscarinic-M(1) receptor actions interfere with cocaine-like effects. Several tropane-nitrogen substitutions of 4',4"-diF-BZT have reduced M(1) affinity compared with the CH(3)-analog (AHN 1-055; 3alpha-[bis-(4-fluorophenyl)methoxy]tropane). All of the compounds displaced [(3)H]WIN 35,428 (2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane) binding with affinities ranging from 11 to 108 nM. Affinities at norepinephrine ([(3)H]nisoxetine) and serotonin ([(3)H]citalopram) transporters ranged from 457 to 4810 and 376 to 3260 nM, respectively, and at muscarinic M(1) receptors ([(3)H]pirenzepine) from 11.6 (AHN 1-055) to higher values, reaching 1030 nM for the other BZT-analogs. Cocaine and AHN 1-055 produced dose-related increases in locomotor activity in mice, with AHN 1-055 less effective than cocaine. The other compounds were ineffective in stimulating activity. In rats discriminating cocaine (29 micromol/kg i.p.) from saline, WIN 35,428 fully substituted for cocaine, whereas AHN 1-055 produced a maximal substitution of 79%. None of the other analogs fully substituted for cocaine. WIN 35,428 produced dose-related leftward shifts in the cocaine dose-effect curve, whereas selected BZT analogs produced minimal changes in the effects of cocaine. The results suggest that reducing M(1) affinity of 4',4"-diF-BZT with N-substitutions reduces effectiveness in potentiating the effects of cocaine. Furthermore, although the BZT-analogs bind with high affinity at the dopamine transporter, their behavioral effects differ from those of cocaine. These compounds have reduced efficacy compared with cocaine, a long duration of action, and may serve as leads for the development of medications to treat cocaine abuse.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755006     DOI: 10.1124/jpet.103.060525

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  40 in total

1.  The Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic.

Authors:  Hai-Ying Zhang; Guo-Hua Bi; Hong-Ju Yang; Yi He; Gilbert Xue; Jiajing Cao; Gianluigi Tanda; Eliot L Gardner; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropsychopharmacology       Date:  2017-03-07       Impact factor: 7.853

2.  Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays.

Authors:  Hideaki Yano; Alessandro Bonifazi; Min Xu; Daryl A Guthrie; Stephanie N Schneck; Ara M Abramyan; Andrew D Fant; W Conrad Hong; Amy H Newman; Lei Shi
Journal:  Neuropharmacology       Date:  2018-01-31       Impact factor: 5.250

3.  Preference for distinct functional conformations of the dopamine transporter alters the relationship between subjective effects of cocaine and stimulation of mesolimbic dopamine.

Authors:  Stephen J Kohut; Takato Hiranita; Soo-Kyung Hong; Aaron L Ebbs; Valeria Tronci; Jennifer Green; Linda Garcés-Ramírez; Lauren E Chun; Maddalena Mereu; Amy H Newman; Jonathan L Katz; Gianluigi Tanda
Journal:  Biol Psychiatry       Date:  2014-04-19       Impact factor: 13.382

4.  The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse.

Authors:  Ahmed A Othman; Amy H Newman; Natalie D Eddington
Journal:  J Pharm Sci       Date:  2008-12       Impact factor: 3.534

5.  Further delineation between typical and atypical dopamine uptake inhibitors: effects on food-maintained behavior and food consumption.

Authors:  Jonathan M Slezak; Rajeev I Desai; Jonathan L Katz
Journal:  Behav Pharmacol       Date:  2017-02       Impact factor: 2.293

6.  σ Receptor Effects of N-Substituted Benztropine Analogs: Implications for Antagonism of Cocaine Self-Administration.

Authors:  Takato Hiranita; Weimin C Hong; Theresa Kopajtic; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2017-04-25       Impact factor: 4.030

7.  The stereotypy-inducing effects of N-substituted benztropine analogs alone and in combination with cocaine do not account for their blockade of cocaine self-administration.

Authors:  Libin Li; Takato Hiranita; Shuichiro Hayashi; Amy H Newman; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2012-09-14       Impact factor: 4.530

8.  Dopamine Transporter Dynamics of N-Substituted Benztropine Analogs with Atypical Behavioral Effects.

Authors:  Weimin C Hong; Michael J Wasko; Derek S Wilkinson; Takato Hiranita; Libin Li; Shuichiro Hayashi; David B Snell; Jeffry D Madura; Christopher K Surratt; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2018-06-26       Impact factor: 4.030

9.  Role of the σRs for Development of Medications.

Authors:  Takato Hiranita
Journal:  J Alcohol Drug Depend       Date:  2013-09-12

10.  The binding sites for cocaine and dopamine in the dopamine transporter overlap.

Authors:  Thijs Beuming; Julie Kniazeff; Marianne L Bergmann; Lei Shi; Luis Gracia; Klaudia Raniszewska; Amy Hauck Newman; Jonathan A Javitch; Harel Weinstein; Ulrik Gether; Claus J Loland
Journal:  Nat Neurosci       Date:  2008-06-22       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.